Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years

Hepatology

Volumn 66, Issue 4, 2017, Pages 1036-1044

  Fung, James ^a,b,c   Wong, Tiffany ^a,b   Chok, Kenneth ^a,b   Chan, Albert ^a,b   Cheung, Tan To ^a,b   Dai, Jeff Wing Chiu ^a,b   Sin, Sui Ling ^a,b   Ma, Ka Wing ^a,b   Ng, Kelvin ^a,b   Ng, Kevin Tak Pan ^b   Seto, Wai Kay ^b,c   Lai, Ching Lung ^b,c   Yuen, Man Fung ^b,c   Lo, Chung Mau ^a,b,c  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; ENTECAVIR; EVEROLIMUS; HEPATITIS B SURFACE ANTIGEN; MYCOPHENOLATE MOFETIL; RAPAMYCIN; TACROLIMUS; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADD ON THERAPY; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER RECURRENCE; CHRONIC HEPATITIS B; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELASTOGRAPH; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER STIFFNESS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; TRANSIENT ELASTOGRAPHY; VIRUS LOAD; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HONG KONG; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; POSTOPERATIVE COMPLICATIONS; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HONG KONG; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 85026544921     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29191     Document Type: Article

References (20)

1. Fung J. Management of chronic hepatitis B before and after liver transplantation. World J Hepatol 2015;7:1421-1426.
2. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813-815.
3. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
4. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai V, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-1303.
5. Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001;233:276-281.
6. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000;70:809-815.
7. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States–Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-432.
8. Lam YF, Seto WK, Fung J, Lai CL, Yuen MF. Continuous entecavir for treatment naive Chinese chronic hepatitis B patients in the real world setting—the seven year results. Hepatol Int 2015;9:S204.
9. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011;141:1212-1219.
10. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013;108:942-948.
11. Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol 2008;23:1182-1192.
12. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis B–related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008;6:696-700.
13. Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 2009;22:387-394.
14. Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010;12:292-308.
15. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen–positive liver transplant candidates. Liver Transpl 2013;19:268-274.
16. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460-1466.
17. Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 2013;19:594-601.
18. Fung J, Lo R, Chan SC, Chok K, Wong T, Sharr W, et al. Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. Liver Transpl 2015;21:1504-1510.
19. Fung J, Lo R, Chan SC, Chok KS, Cheung C, Cheung TT, et al. Risk of recurrent hepatocellular carcinoma in chronic hepatitis B patients after liver transplantation. Liver Transpl 2013;19:S157.
20. Yang YJ, Shim JH, Kim KM, Lim YS, Lee HC. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology 2014;59:1303-1310.